Back to top
more

Merck & Co. (MRK)

(Real Time Quote from BATS)

$104.22 USD

104.22
3,147,585

+0.24 (0.23%)

Updated Oct 28, 2024 01:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 14% (36 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals

Coca-Cola, Merck, Toyota Motor, Enbridge, and Regeneron Pharmaceuticals are part of Zacks top Analyst Blog.

Mark Vickery headshot

Top Stock Reports for Coca-Cola, Merck & Toyota Motor

Today's Research Daily features new research reports on 16 major stocks, including The Coca-Cola Company (KO), Merck & Co., Inc. (MRK) and Toyota Motor Corp. (TM).

Moderna (MRNA) Bivalent COVID Booster Effective Against BA.4/5

Moderna's (MRNA) bivalent COVID booster candidate exhibits a higher antibody response against all-tested COVID-19 variants, including the Omicron subvariants BA.4 and BA.5.

Exelixis (EXEL) Cabometyx Combo Study Meets Primary Goal

Exelixis'(EXEL) late-stage study evaluating the combination of Cabometyx and Opdivo and Yervoy demonstrates significant improvement in progression-free survival at the primary analysis.

Pliant Therapeutics (PLRX) Up on Positive Data From Lung Disease Study

Pliant Therapeutics (PLRX) reports favorable data from a mid-stage study, which supports the potential of PLN-74809, its experimental drug candidate for treating IPF.

Here's Why You Should Retain Walgreens Boots (WBA) For Now

Investors are optimistic about Walgreens Boots (WBA), given its better-than-expected earnings and strategic alliances.

Looking for Medical Stocks? The Zacks Rank Can Help You Find Winners

The Zacks Rank offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage.

PFE, BNTX's COVID Jab Gets FDA's Full Nod for Adolescents

Pfizer (PFE) and partner BioNTech's (BNTX) Comirnaty is the first COVID-19 vaccine to receive full approval in the United States for use in adolescents aged 12 years and older.

Henry Schein's (HSIC) New Buyout Expands Its Switzerland Base

Henry Schein (HSIC) serves the Swiss dental implant market through its Basel-based division, Camlog Biotechnologies GmbH, since 2004.

Quest Diagnostics (DGX), CDC Sign New COVID-19 Testing Deal

Quest Diagnostics (DGX) and the CDC tie up to provide COVID testing for underserved communities free of cost across the United States.

The Zacks Analyst Blog Highlights Coca-Cola, Home Depot, Merck and JPMorgan Chase

Coca-Cola, Home Depot, Merck and JPMorgan Chase are part of Zacks Top Analyst Blog.

Derek Lewis headshot

3 Large-Cap Stocks up More Than 20% Year-To-Date

All three sport strong Zacks Ranks - a significant perk that instills confidence in these companies' share performances moving forward.

LabCorp's (LH) Base Testing Volume Grows, Costs Rise

LabCorp's (LH) slew of product launches and collaborations to pursue short- and long-term high-growth opportunities instill optimism.

Here's Why You Should Retain Haemonetics (HAE) Stock For Now

Investors are optimistic about Haemonetics' (HAE) robust performances across the Hospital and Plasma businesses.

Intercept (ICPT) Reports Positive Data From NASH Study on OCA

Intercept (ICPT) reports positive top-line results from a new analysis of its ongoing pivotal phase III REGENERATE study of OCA in patients with liver fibrosis due to NASH.

Nalak Das headshot

Buy These 4 Blue-Chip Stocks to Strengthen Your Portfolio

We have narrowed our search to four Dow stocks. These are: HD, KO, MRK and JPM.

Merck (MRK) Stock Sinks As Market Gains: What You Should Know

Merck (MRK) closed at $93.01 in the latest trading session, marking a -0.13% move from the prior day.

Merck (MRK) in Advanced Talks to Buy Seagen (SGEN) Per WSJ

Reportedly, Merck (MRK) could offer at least $40 billion to buy Seagen (SGEN). If both companies go through with the deal, it will expand Merck's oncology portfolio/pipeline.

Bruker (BRKR) Debuts NMR Test for Research on Long COVID Risks

Bruker's (BRKR) PhenoRisk PACS RuO will facilitate clinical research to combat the risks of Long COVID syndrome.

Intercept (ICPT) Ocaliva Drives Growth, Pipeline Setbacks Hurt

Intercept (ICPT) currently has only one marketed product in its portfolio, Ocaliva, for treating PBC. The company continues to evaluate the potential of OCA in treating progressive liver diseases.

Is Most-Watched Stock Merck & Co., Inc. (MRK) Worth Betting on Now?

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Roche's (RHHBY) Lunsumio Application Gets Priority Review

Roche's (RHHBY) BLA application seeking approval for the use of Lunsumio for relapsed or refractory follicular lymphoma has been granted priority review in the United States.

Here's Why You Should Retain Edwards Lifesciences (EW) Now

Investors are optimistic about Edwards Lifesciences' (EW) strong segmental performance and the growing demand for its RESILIA tissue valves.

Reasons Why You Should Invest in ResMed (RMD) Stock Now

Investors are optimistic about ResMed's (RMD) robust mask and device sales and continued product innovations.

Tandem Diabetes (TNDM) New Launches Aid Growth Amid Cost Woes

Tandem Diabetes (TNDM) witnesses strong customer retention, driven by the impressive positive response from the Control-IQ technology.